Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
How are you integrating the findings from KEYNOTE-689 into daily practice?
Related Questions
What is the role of adjuvant RT for metastatic RCC to the thyroid resected with high-risk features?
What is your recommendation for patients who are on weight loss medications like GLP-1-based therapies while receiving chemoradiation for head and neck cancer?
How do you manage a twice-recurrent mucinous adenocarcinoma of the lower eyelid with direct involvement of the lateral rectus muscle and lacrimal duct?
How would you manage a presumed radiation induced sarcoma of the head and neck?
How do you approach cisplatin dosing for locally advanced head and neck SCC in HPV-positive and HPV-negative patients?
The 2025 multigroup consensus guidelines for target delineation of NPC recommend GTVp to CTVp expansion of 0mm (previously 5mm in the 2017 guidelines). What do you do in your practice?
What is the role for chemo immunotherapy in the up front setting in non-metastatic head & neck cancer outside of clinical trials?
For a patient s/p TORS with indications for adjuvant radiation, how does your management change with persistently elevated ctHPVDNA?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
How would the updated results of ECOG 3311 influence your adjuvant RT recommendations for HPV+ OPSCC?
